Close Menu

North America

Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.

The firm's full fiscal year revenues were also up, 32 percent as reported, or about 6 percent on a currency-neutral basis.

The Vitros HIV Combo test is a fourth-generation test that detects HIV-1 and HV-2 antibodies, and the p24 antigen, resulting in earlier detections of the disease.

Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.

Company officials stressed the firm's drive to help connect industry and academia, and expand access to tools for precision medicine.

Newly announced changes will enable more hospital outreach laboratories to submit lab pricing data, but lab groups say more changes are needed.

The firm has filed for CE marking for the initial MosaiQ IH microarray and anticipates filing for its first serological disease screening microarray during the first half of 2019.

The firm anticipates that in 2019 it will begin clinical trials for a comprehensive metabolic panel for use on its point-of-care platform.

Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.

The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.

Pages